SHANGHAI – Adagene Inc., of Suzhou, has raised $8 million in series A financing from a consortium of backers, including Fidelity Biosciences, Fidelity Asia Growth and Wuxi Venture Fund, an investment vehicle for Wuxi Apptec. First established in 2011, Adagene, an antibody discovery company, has been quietly developing its technology and is gearing up for its next stage of development. Read More

NEW DELHI – India's leading cancer treatment hospital has requested the country's drug pricing regulator to delete three cancer drugs from its national list of essential medicines (NLEM), and instead add a dozen others. The regulator has put up the list in the public domain for feedback, before taking a decision. Read More

HONG KONG – The elucidation of the core structure of a secretory channel in the bacterial outer membrane may provide a target for the development of novel antibiotics aimed at attenuating biofilm formation, Chinese scientists report in the Dec. 1, 2014, early online edition of the Proceedings of the National Academy of Sciences. Read More

HONG KONG – Home to large populations and steadily growing economies, Asia is poised to serve as an important growth region for pharmaceuticals for decades to come. Read More

SHANGHAI – Canbridge Life Sciences Inc., a Beijing-based biopharma company started in 2012 with angel and private capital, has received $10 million in a series A investment from leading local health care venture capital funds Qiming Ventures and TF Capital. The investment will be used to further Canbridge's two existing in-licensed programs and put cash in its pocket to bring in more assets. Read More

60P Australia Pty Ltd., a subsidiary of 60° Pharmaceuticals LLC, of Washington, has entered an exclusive partnering deal with Monash University obtaining rights to develop the drug fenretinide for dengue fever. Terms were not disclosed. Read More